bullish
Pre-IPO New Ruipeng Pet Group (RPET.US)- The Industry, the Business and the Concerns
282 Views30 Jan 2023 08:55
Pet hospital, with dual attributes of medical treatment and consumption, has huge development potential. New Ruipeng has rapid growth, but low gross margin and other concerns could be the challenges.
Xinyao has highlighted this Insight as a Top Pick
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Alphamab Co Ltd Placement (9966.HK) - Has No Potential to Be a Biopharma; Just Remain as a Biotech06 Feb 2023
- China Healthcare Weekly (Feb.3)- CanSino, Blood Products Shortage, Don't Be Greedy in Front of Rally05 Feb 2023
- Pre-IPO Changchun BCHT Biotechnology - The Risk of Single-Product Dependence and Uncertain Outlook02 Feb 2023
- Pre-IPO New Ruipeng Pet Group (RPET.US)- The Industry, the Business and the Concerns30 Jan 2023
- Pre-IPO CanSino Biologics - 2022 Annual Results May Be Ugly as MCV4 Commercialization Hit a Snag26 Jan 2023
- China Healthcare Weekly (Jan.20) - NRDL Negotiation Results, JW Therapeutics, Sirnaomics, Antengene23 Jan 2023
- Industry Report - Insights on China Pet Medical Industry11 Feb 2021
x